Human Papillomavirus Genotype Distribution Among 18,815 Women in 13 Korean Cities and Relationship With Cervical Cytology Findings
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background: The prevalence and genotype distribution of Human papillomavirus (HPV) infection vary depending on geographical region and the immunity provided by vaccines. This study aimed to clarify the recent prevalence and genotype distribution of HPV according to age and cervical cytology findings in Korea. Methods: This study included 18,815 health examinees that underwent cervical cytology and HPV genotyping tests at 16 centers of Korean Association of Health Promotion in 13 cities in Korea, between January 2014 and October 2015. HPV was genotyped by using multiplex PCR (Anyplex II HPV 28, Seegene, Korea), which detects 19 high-risk HPVs (HR-HPV) and nine low-risk HPVs (LR-HPV). Results: Overall HPV prevalence was 27.8%, with 22.2% HR-HPV and 11.4% LR-HPV. The five most common carcinogens were HPV 52 (3.2%), 58 (2.7%), 16 (2.0%), 56 (1.9%), and 51 (1.8%). The five most common HR-HPVs in normal cytology samples were HPV 53, 68, 70, 52, and 58, while HPV 16, 52, 58, 33, and 31 were prevalent in high grade squamous intraepithelial lesions (HSIL). In atypical squamous cells of undetermined significance (ASCUS), the prevalence of HR-HPV varied with age; it was highest in those aged <30 yr, declining to a minimum at age 50–59 yr, and then increasing in older women (P<0.05). Conclusions: The prevalence and distribution of HR-HPV varied with age and cervical cytology findings. This information would be helpful in the development of cervical cancer prevention policies.
Abstract
Background: The prevalence and genotype distribution of Human papillomavirus (HPV) infection vary depending on geographical region and the immunity provided by vaccines. This study aimed to clarify the recent prevalence and genotype distribution of HPV according to age and cervical cytology findings in Korea. Methods: This study included 18,815 health examinees that underwent cervical cytology and HPV genotyping tests at 16 centers of Korean Association of Health Promotion in 13 cities in Korea, between January 2014 and October 2015. HPV was genotyped by using multiplex PCR (Anyplex II HPV 28, Seegene, Korea), which detects 19 high-risk HPVs (HR-HPV) and nine low-risk HPVs (LR-HPV). Results: Overall HPV prevalence was 27.8%, with 22.2% HR-HPV and 11.4% LR-HPV. The five most common carcinogens were HPV 52 (3.2%), 58 (2.7%), 16 (2.0%), 56 (1.9%), and 51 (1.8%). The five most common HR-HPVs in normal cytology samples were HPV 53, 68, 70, 52, and 58, while HPV 16, 52, 58, 33, and 31 were prevalent in high grade squamous intraepithelial lesions (HSIL). In atypical squamous cells of undetermined significance (ASCUS), the prevalence of HR-HPV varied with age; it was highest in those aged <30 yr, declining to a minimum at age 50–59 yr, and then increasing in older women (P<0.05). Conclusions: The prevalence and distribution of HR-HPV varied with age and cervical cytology findings. This information would be helpful in the development of cervical cancer prevention policies.
참고문헌 (27)
- Torre LA, "Global cancer statistics, 2012", CA Cancer J Clin, 65, pp.87~108 (2015)
- Annual report of cancer statistics in Korea in 2014, "National Cancer Center", National Cancer Center, 20~22 (2014)
- Meijer CJ, "Clinical utility of HPV genotyping", Gynecol Oncol, 103, pp.12~17 (2006)
- Saslow D, "American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer", Am J Clin Pathol, 137, pp.516~542 (2012)
- Bernard HU, "Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments", Virology, 401, pp.70~79 (2010)
- de Sanjosé S, "Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis", Lancet Infect Dis, 7, pp.453~459 (2007)
- Bae, Jeong-Hoon, "Human Papillomavirus (HPV) Type Distribution in Korean Women: A Meta-Analysis", Journal of Microbiology and Biotechnology, 18(4), pp.788~794 (2008), 한국미생물·생명공학회
- 김민정, "Type-specific prevalence of high-risk human papillomavirus by cervical cytology and age: Data from the health check-ups of 7,014 Korean women", Obstetrics & Gynecology Science, 56(02), pp.110~120 (2013), 대한산부인과학회[DOI]
- Shin HR, "Prevalence of human papillomavirus infection in women in Busan, South Korea", Int J Cancer, 103, pp.413~421 (2003)
- Solomon D, "The 2001 Bethesda System: terminology for reporting results of cervical cytology", JAMA, 287, pp.2114~2119 (2002)
- Schiffman M, "Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline", Infect Agent Cancer, 4, pp.8~ (2009)
- "Agents classified by the IARC monographs, vol. 1-118"[URL]
- 김재경, "Prevalence and Genotype Distribution of Human Papillomavirus in Cheonan, Korea", Journal of Microbiology and Biotechnology, 24(8), pp.1143~1147 (2014), 한국미생물·생명공학회[DOI]
- 이은희, "Prevalence and Distribution of Human Papillomavirus Infection in Korean Women as Determined by Restriction Fragment Mass Polymorphism Assay", Journal of Korean Medical Science, 27(9), pp.1091~1097 (2012), 대한의학회
- Rhee JE, "Prevalence of human papillomavirus infection and genotype distribution among high-risk Korean women for prospecting the strategy of vaccine development", Virol J, 7, pp.201~ (2010)
- Mesher D, "Continuing reductions in HPV 16", 18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study, 2016, pp.6, e009915~
- Markowitz LE, "Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010", J Infect Dis, 208, pp.385~393 (2013)
- Tabrizi SN, "Fall in human papillomavirus prevalence following a national vaccination program", J Infect Dis, 206, pp.1645~1651 (2012)
- Heard I, "Human papillomavirus types distribution in organised cervical cancer screening in France", PLoS One, 8, pp.e79372~ (2013)
- Howell-Jones R, "Multi-site study of HPV type-specific prevalence in women with cervical cancer, intraepithelial neoplasia and normal cytology, in England", Br J Cancer, 103, pp.209~216 (2010)
- Bosch FX, "Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia", Vaccine, 26(S10), pp.K1~K16 (2008)
- Malagón T, "Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis", Lancet Infect Dis, 12, pp.781~789 (2012)
- Wheeler CM, "Cross-protective efficacy of HPV-16", 18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial, 2012, pp.13, 100~110
- Franceschi S, "Variations in the age-specific curves of human papillomavirus prevalence in women worldwide", Int J Cancer, 119, pp.2677~2684 (2006)
- Gravitt PE, "A cohort effect of the sexual revolution may be masking an increase in human papillomavirus detection at menopause in the United States", J Infect Dis, 207, pp.272~280 (2013)
- Althoff KN, "Correlates of cervicovaginal human papillomavirus detection in perimenopausal women", J Womens Health (Larchmt), 18, pp.1341~1346 (2009)
- Muñoz N, "Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results", J Infect Dis, 190, pp.2077~2087 (2004)